Long-term results and pharmacokinetics of high-dose paclitaxel in patients with refractory epithelial ovarian carcinoma

International Journal of Gynecological Cancer

Volumn 9, Issue 1, 1999, Pages 44-53

  Kudelka, A P ^a   Verschraegen, C F ^a   Shen, Y ^a   Gonzalez De Leon, C ^a   Edwards, C L ^a   Freedman, R S ^a   Forman, A ^a   Gibbs, H R ^a   Mante, R ^a   Hord, M ^a   Canetta, R ^b   Krakoff, I ^a   Kavanagh, J J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

Dose intensity; Ovarian neoplasms; Platinum resistance; Taxane

Indexed keywords

PACLITAXEL;

ADULT; AGED; ALOPECIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NEUROTOXICITY; NEUTROPENIA; OVARY CARCINOMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMATITIS; TREATMENT OUTCOME;

EID: 6544295891     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1438.1999.09856.x     Document Type: Article

References (28)

1. Greene MH, Clark JW, Blayney DW. The epidemiology of ovarian cancer. Semin Oncol 1984; 11: 209-26.
2. Griffiths CT, Fuller AF. Intensive surgical and chemotherapeutic management of advanced ovarian cancer. Surg Clin North Am 1978; 58: 131-42.
3. Thigpen JT, Vance RB, Lambuth BW. Ovarian carcinoma: the role of chemotherapy. Semin Oncol 1988; 15: 16-23.
4. McGuire WP, Rowinsky EK, Rosenshein NB et al. Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Int Med 1989; 111: 273-9.
5. Jordan MA, Wilson L. Microtubule polymerization dynamics, mitotic block, and cell death by paclitaxel at low concentrations. In: Geor GI, Chen TT, Ojima I, Vyas DM, eds. Taxane Anticancer Agents: Basic Science and Current Status. Washington, DC: American Chemical Society. 1995:138-51.
6. Jordan MA, Toso RJ, Thrower D et al. Mechanism of mitotic block and inhibition of cell proliferation by Taxol at low concentrations. Proc Natl Acad Sci USA 1993; 90: 9552-6.
7. McGuire WP, Hoskins WJ, Brady MF et al. Taxol and cisplatin improve outcome in advanced ovarian cancer as compared to cytoxan and cisplatin. Proc Am Soc Clin Oncol 1995; 14: 275.
8. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion. J Clin Oncol 1994; 12: 2654-66.
9. WHO. Handbook for Reporting Results of Cancer Treatment. Geneva: World Health Organization. 1979: 48.
10. Spitzer WO. Measuring the quality of life of cancer patients: A concise QL-Index for use by physicians. J Chron Dis 1981; 34: 585-97.
11. Willey TA, Bekos EJ, Gaver RC, Duncan GF, Tay LK. High-performance liquid Chromatographic procedure determination of paclitaxel in human plasma. J Chromatogr 1993; 621: 231-8.
12. Farmen RH, Muniak JF, Pittman KA. Management of pharmacokinetic data using HP-3357/Mainframe IBM interfacing. Drug Inform J 1987; 21: 141-52.
13. Riegelman S, Collier P. An application of statistical moment theory to the evaluation of in vivo dissolution time and absorption time. J Pharmacokinet Biopharm 1984; 8: 509-34.
14. Peto J. The calculation and interpretation of survival curves. In: Buyse M, Staquet M, Sylvester R, eds. Cancer Clinical Trials: Methods and Practice. Oxford: Oxford University Press 1984: 361-80.
15. Thigpen JT, Blessing JA, Ball H et al. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: A Gynecologic Oncology Group study. J Clin Oncol 1994; 12: 1748-53.
16. Kohn E, Sarosy G, Bicher A et al. Dose-intense Taxol: High response rate in patients with platinum-resistant recurrent ovarian cancer. J Natl Cancer Inst 1994; 86: 18-24.
17. Sonnichsen DS, Relling MV. Clinical pharmacokinetics of paclitaxel. Clin Pharmacokinet 1994; 27: 256-69.
18. Sonnichsen DS, Hurwitz CA, Pratt CB, Shuster JJ, Relling MV. Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors. J Clin Oncol 1994; 12: 532-8.
19. Longnecker SM, Donehower RC, Cates AE et al. High-performance liquid Chromatographic assay for paclitaxel in human plasma and urine and pharmacokinetics in a phase I trial. Cancer Treat Rep 1987; 71: 53-9.
20. Wiernik PH, Schwartz EL, Strauman JJ et al. Phase I clinical and pharmacokinetic study of paclitaxel. Cancer Res 1987; 47: 2486-93.
21. Wiernik PH, Schwartz EL, Einzig A et al. Phase I trial of paclitaxel given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma. J Clin Oncol 1987; 5: 1232-9.
22. 2 dose in combination with granulocyte-colony stimulating factor in patients with ovarian cancer. Cancer Chemother Pharmacol 1993; 33: 48-52.
23. Omura GA, Brady JE, Delmore HJ et al. A randomized trial of paclitaxel at 2 dose levels and Filgrastim at 2 doses in platinum pretreated epithelial ovarian cancer: a Gynecologic Oncology Group, SWOG, NCCTG, and ECOG Study. Proc Am Soc Clin Oncol 1996; 15: 280.
24. Einzig AI, Wiernik H, Sasloff J et al. Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma. J Clin Oncol 1992; 10: 1748-53.
25. Trimble EL, Adams JD, Vena D et al. Paclitaxel for platinum-refractory ovarian cancer: Results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103. J Clin Oncol 1993; 11: 2405-10.
26. Kudelka AP, De Leon Gonzalez C, Creighton E et al. Paclitaxel in patients with platinum-resistant ovarian cancer: A selected review of literature and clinical experience. J Med Assoc Thai 1996; 79: 240-4.
27. Seewaldt VL, Greer BE, Cain JM et al. Paclitaxel (Taxol) treatment for refractory ovarian cancer: Phase II clinical trial. Am J Obstet Gynecol 1994; 170: 1666-71.
28. Phillips KA, Friedlander M, Olver I et al. Australasian multicentre phase II study of paclitaxel (Taxol) in relapsed ovarian cancer. Aust NZ J Med 1995; 25: 337-43.